Campbell & Co Investment Adviser’s Standard BioTools LAB Stock Holding History

Campbell & Co Investment Adviser’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-98,000	Closed	-$384K	–	800
2021 Q4	$384K	Buy	+98,000	New	+$459K	0.13%	276
2018 Q4	–	Sell	-15,600	Closed	-$117K	–	419
2018 Q3	$117K	Buy	+15,600	New	+$111K	0.08%	371
2015 Q4	–	Sell	-19,741	Closed	-$160K	–	155
2015 Q3	$160K	Buy	+19,741	New	+$311K	0.11%	284

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Campbell & Co Investment Adviser's LAB Position: Q1 2022 in Review

Campbell & Co Investment Adviser sold out of Standard BioTools (LAB) in Q1 2022, closing a stake of 98,000 shares — an estimated $384K sold.

Campbell & Co Investment Adviser first reported a position in LAB in Q3 2015 and held it in 3 quarters. The position peaked at $384K in Q4 2021. 109 funds tracked by Wall St. Rank hold LAB as of Q1 2022.

Campbell & Co Investment Adviser reported no remaining Standard BioTools position as of Q1 2022 after selling out during the quarter.
Campbell & Co Investment Adviser sold 98,000 Standard BioTools shares in Q1 2022, an estimated $384K.
Campbell & Co Investment Adviser first reported a position in Standard BioTools in Q3 2015 and held it in 3 quarters.
Campbell & Co Investment Adviser's Standard BioTools position peaked at $384K in Q4 2021.
109 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2022, filed 9 May 2022.